Verywell Health on MSN2d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...
ScienceAlert on MSN6d
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
Boing Boing on MSN6d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...
That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week for four weeks. However, it has a broader label as ...
They could also be cheaper, given that Spravato's US list price in the US is $590 to $885 for two doses. “Use of an extended-release oral dosage ketamine formulation may be advantageous compared ...
US FDA OKs monthly maintenance dosing for Eisai/Biogen's ... expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback